Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate the superiority of gevokizumab as compared to
placebo on top of current standard of care in reducing the risk of Behçet's disease uveitis
exacerbations
Phase:
Phase 3
Details
Lead Sponsor:
Institut de Recherches Internationales Servier Servier